2-(4-chlorophenoxy)-N-cyclohexylacetamide | 349455-77-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-(4-chlorophenoxy)-N-cyclohexylacetamide
• CAS: 349455-77-2
• 化学式: C₁₄H₁₈ClNO₂
• 分子量: 267.755
• InChiKey: BDCZRWBEIVVXFK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(4-chlorophenoxy)-N-cyclohexylacetamide 、 乙基溴化镁 在 2-氟吡啶 、 三氟甲磺酸酐 、 盐酸 、 水 作用下， 以 二氯甲烷 、 四氢呋喃 为溶剂， 反应 2.42h， 以87%的产率得到1-(4-chlorophenoxy)-butane-2-one
  参考文献：
  名称：

  通过将有机金属试剂加入仲酰胺化学选择性合成酮和酮亚胺

  摘要：

  高效和选择性转化的发展在合成化学中至关重要，因为它为复杂分子的全合成开辟了新的可能性。将此类反应应用于酮的合成非常重要，因为该基序可作为合成众多有机功能的手柄。在这种情况下，我们报告了一种基于仲酰胺活化/加成序列的通用化学选择性方法，允许控制分离结构不同的酮和酮亚胺。发现高度亲电子的亚胺酰基三氟甲磺酸酯中间体的产生在观察到的异常官能团耐受性中起关键作用，允许将现成的格氏试剂和二有机锌试剂轻松添加到酰胺中，避免常见的过度加成或还原副反应。该方法已应用于抗肿瘤剂 Bexarotene 类似物的正式合成，以及在一锅法中快速有效地合成不对称二酮。

  DOI：

  10.1038/nchem.1268

文献信息

• PERK AND IRE-1A INHIBITORS AGAINST NEURODEVELOPMENTAL DISORDERS
  申请人：Université de Liège

  公开号：EP3656382A1

  公开（公告）日：2020-05-27

  The present invention relates to UPR pathway inhibitors, in particular PERK and IRE-1A inhibitors for use in the prevention or treatment of neurodevelopmental disorders, such as microcephaly caused by ZIKV.

  本发明涉及 UPR 通路抑制剂，特别是 PERK 和 IRE-1A 抑制剂，用于预防或治疗神经发育障碍，如 ZIKV 引起的小头畸形。
• Modulators of the eIF2alpha pathway
  申请人：The Regents of the University of California

  公开号：US10343981B2

  公开（公告）日：2019-07-09

  Provided herein, inter alia, are compounds and methods useful for modulating the translational effects of eIF2α phosphorylation, the Integrated Stress Response (ISR), and the unfolded protein response (UPR); for treating diseases; for increasing protein production, and for improving long-term memory.

  本文提供的化合物和方法主要用于调节 eIF2α 磷酸化、综合应激反应（ISR）和未折叠蛋白反应（UPR）的翻译效应；治疗疾病；增加蛋白质产量以及改善长期记忆。
• MODULATORS OF THE EIF2ALPHA PATHWAY
  申请人：The Regents of the University of California

  公开号：US20170342020A1

  公开（公告）日：2017-11-30

  Provided herein, inter alia, are compounds and methods useful for modulating the translational effects of eIF2α phosphorylation, the Integrated Stress Response (ISR), and the unfolded protein response (UPR); for treating diseases; for increasing protein production, and for improving long-term memory.
• PREVENTIVE AND THERAPEUTIC APPROACH FOR ABERRANT CELL DIFFERENTIATION AND ISR-ASSOCIATED DISEASES
  申请人：The University of Hong Kong

  公开号：US20190240171A1

  公开（公告）日：2019-08-08

  The present invention describes a method of preventing, ameliorating and/or treating disorders or diseases associated with the integrated stress response (ISR) involving the p-eIF2α pathway arising from various cellular stresses such as oxidative stress, hypoxia and ER stress, chronic or prolonged bio-mechanical stress. In one embodiment, the present invention provides a method which prevents or alleviates aberrant cell differentiation that is caused by the activation of the integrated stress response and thereby prevents or alleviates conditions, disorders or diseases resulting therefrom. In one embodiment, ISR-associated diseases subject to the present invention include but are not limited to skeletal disorders including disc degeneration, MCDS and other skeletal dysplasias, cancers, inflammatory diseases, diabetes, fibrosis, obesity and neurodegenerative diseases. In another embodiment, the present invention provides a method of using a p-eIF2α-modulator for the prevention or treatment of conditions, disorders or diseases described herein.
• US9708247B2
  申请人：——

  公开号：US9708247B2

  公开（公告）日：2017-07-18